Key result
Pharmacological RAS inhibition significantly reduced systolic blood pressure (from 159 to 126 mmHg in hypertensive rats) and proteinuria, indicating RAS contributes to disease progression.
Why the study?
Does pharmacological RAS inhibition reduce blood pressure and proteinuria in fawn-hooded hypertensive rats?
Does pharmacological RAS inhibition reduce blood pressure and proteinuria in fawn-hooded hypertensive rats?
Answers are grounded in this paper and cite their sources.
In a genetic rat model of spontaneous hypertension, RAS inhibition reduced blood pressure and proteinuria, suggesting that RAS contributes to hypertension and kidney disease progression despite no observed elevation in plasma and renal RAS levels.
The fawn-hooded hypertensive (FHH) rat serves as a genetic model of spontaneous hypertension associated with glomerular hyperfiltration and proteinuria. However, the knowledge of the natural course of hypertension and kidney disease in FHH rats remains fragmentary and the underlying pathophysiological mechanisms are unclear. In this study, over the animals' lifetime, we followed the survival rate, blood pressure (telemetry), indices of kidney damage, the activity of renin-angiotensin (RAS) and nitric oxide (NO) systems, and CYP450-epoxygenase products (EETs). Compared to normotensive controls, no elevation of plasma and renal RAS was observed in prehypertensive and hypertensive FHH rats; however, RAS inhibition significantly reduced systolic blood pressure (137 ± 9 to 116 ± 8, and 159 ± 8 to 126 ± 4 mmHg, respectively) and proteinuria (62 ± 2 to 37 ± 3, and 132 ± 8 to 87 ± 5 mg/day, respectively). Moreover, pharmacological RAS inhibition reduced angiotensin (ANG) II and increased ANG 1-7 in the kidney and thereby may have delayed the progression of kidney disease. Furthermore, renal NO and EETs declined in the aging FHH rats but not in the control strain. The present results, especially the demonstration of exaggerated vascular responsiveness to ANG II, indicate that RAS may contribute to the development of hypertension and kidney disease in FHH rats. The activity of factors opposing the development of hypertension and protecting the kidney declined with age in this model. Therefore, therapeutic enhancement of this activity besides RAS inhibition could be attempted in the therapy of human hypertension associated with kidney disease.
No takes yet. Share an insight, caveat, or question.
Doleželová et al. (2016) studied Hypertension and kidney disease. Pharmacological RAS inhibition vs. Untreated FHH rats / normotensive controls was evaluated on Systolic blood pressure and proteinuria. Pharmacological RAS inhibition significantly reduced systolic blood pressure (from 159 to 126 mmHg in hypertensive rats) and proteinuria, indicating RAS contributes to disease progression.
Synapse has enriched 10 related papers. Consider them for comparative context: